Results 281 to 290 of about 39,319 (333)
Quantitative Systems Pharmacology Model to Predict Target Occupancy by Bruton Tyrosine Kinase Inhibitors in Patients With B-Cell Malignancies. [PDF]
Demin O+10 more
europepmc +1 more source
Longitudinal omics data and preclinical treatment suggest the proteasome inhibitor carfilzomib as therapy for ibrutinib-resistant CLL. [PDF]
Arseni L+25 more
europepmc +1 more source
PURPOSE Among Bruton's tyrosine kinase inhibitors, acalabrutinib has greater selectivity than ibrutinib, which we hypothesized would improve continuous therapy tolerability.
Richard R Furman+2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Blood, 2023
Key Points • Acalabrutinib has a favorable benefit-risk profile, including lower incidence of cardiovascular-related toxicities, vs ibrutinib.• AE burden score allowed further comparison of the safety of acalabrutinib vs ibrutinib accounting for AE ...
J. Seymour+17 more
semanticscholar +1 more source
Key Points • Acalabrutinib has a favorable benefit-risk profile, including lower incidence of cardiovascular-related toxicities, vs ibrutinib.• AE burden score allowed further comparison of the safety of acalabrutinib vs ibrutinib accounting for AE ...
J. Seymour+17 more
semanticscholar +1 more source
Blood, 2023
The final analysis of the open-label, multicenter phase 2 CLL2-GIVe trial shows response and tolerability of the triple combination of obinutuzumab, ibrutinib and venetoclax ("GIVe" regimen) in 41 previously untreated high-risk patients with chronic ...
H. Huber+24 more
semanticscholar +1 more source
The final analysis of the open-label, multicenter phase 2 CLL2-GIVe trial shows response and tolerability of the triple combination of obinutuzumab, ibrutinib and venetoclax ("GIVe" regimen) in 41 previously untreated high-risk patients with chronic ...
H. Huber+24 more
semanticscholar +1 more source
Blood, 2023
CD19-directed chimeric antigen receptor T-cells achieve high response rates in patients with relapsed or refractory mantle cell lymphoma. However, their use is associated with significant toxicity, relapse is a concern, and their broad tractability is ...
A. Minson+20 more
semanticscholar +1 more source
CD19-directed chimeric antigen receptor T-cells achieve high response rates in patients with relapsed or refractory mantle cell lymphoma. However, their use is associated with significant toxicity, relapse is a concern, and their broad tractability is ...
A. Minson+20 more
semanticscholar +1 more source
PURPOSE Ibrutinib has shown activity in non-germinal center B-cell diffuse large B-cell lymphoma (DLBCL). This double-blind phase III study evaluated ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in ...
Anas Younes+2 more
exaly +2 more sources